Sagimet Biosciences Inc.
SGMTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from. The company carries a $448.9M market cap, placing it firmly in the small-cap category. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Market Cap
$448.9M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-5.54
EPS (TTM)
$-1.35
EPS (Fwd)
$-1.31
ROE
-36.0%
ROA
-24.0%
Cash
$104.5M
Total Debt
$39,000
Free CF
-$27.6M
52W Change
104.8%
Annual Financials
Cash vs Debt
With $104.5M in cash and $39K in debt, SGMT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$27.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -36.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, SGMT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SGMT.